MCID: MCC002
MIFTS: 47

Mucocutaneous Leishmaniasis

Categories: Infectious diseases, Respiratory diseases

Aliases & Classifications for Mucocutaneous Leishmaniasis

MalaCards integrated aliases for Mucocutaneous Leishmaniasis:

Name: Mucocutaneous Leishmaniasis 12 15 17 70 32
American Cutaneous Leishmaniasis 12 70
Mucocutaneous Leishmaniasis, American 12
American Mucocutaneous Leishmaniasis 12
Cutaneous Leishmaniasis, American 12
New World Cutaneous Leishmaniasis 12
Leishmaniasis, Mucocutaneous 44

Classifications:



External Ids:

Disease Ontology 12 DOID:9155
ICD9CM 34 085.5
MeSH 44 D007897
SNOMED-CT 67 721813000
ICD10 32 B55.2
UMLS 70 C1328252 C3495436

Summaries for Mucocutaneous Leishmaniasis

Disease Ontology : 12 A leishmaniasis that involves a chronic inflammatory process involving the nasal, pharyngeal, and laryngeal mucosa, which can lead to extensive tissue destruction, caused by protozoan parasites belonging to the genus Leishmania. The infection is characterized by granulomatous lesion which can destroy upper respiratory tract mucosa.

MalaCards based summary : Mucocutaneous Leishmaniasis, also known as american cutaneous leishmaniasis, is related to granulomatous dermatitis and facial paralysis. An important gene associated with Mucocutaneous Leishmaniasis is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Paromomycin and Miltefosine have been mentioned in the context of this disorder. Affiliated tissues include t cells, monocytes and tongue, and related phenotypes are cellular and endocrine/exocrine gland

Related Diseases for Mucocutaneous Leishmaniasis

Diseases related to Mucocutaneous Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 629)
# Related Disease Score Top Affiliating Genes
1 granulomatous dermatitis 30.5 TNF CD8A CD4
2 facial paralysis 30.4 TNF CD8A CD4
3 cytokine deficiency 30.3 IL5 IL13
4 syphilis 30.1 TNF IFNG CD8A CD4
5 keratitis, hereditary 30.1 TNF IL10 CD8A CD4
6 chagas disease 30.0 TNF IL4 IL2 IL10 IFNG CD4
7 amebiasis 30.0 TNF IL4 IL10 HSPA4 CD4
8 pemphigus 30.0 TNF IL4 IL10
9 cellulitis 30.0 TNF IL5 CD8A CD4
10 lymphadenitis 30.0 TNF IL10 IFNG CD4
11 tuberculoid leprosy 29.9 TNF IL2 IL10 IFNG CD4
12 lepromatous leprosy 29.9 TNF IL4 IL2 IL10 IFNG
13 pancytopenia 29.8 IFNG H2AC18 CD8A CD4
14 pulmonary tuberculosis 29.7 TNF IL4 IL2 IL10 IFNG
15 paracoccidioidomycosis 29.7 TNF IL5 IL4 IL2 IL10 IFNG
16 granulomatosis with polyangiitis 29.7 TNF TLR9 IL5 CD4
17 trichinosis 29.7 IL5 IL4 IL13 IL10 CD4
18 dacryoadenitis 29.7 IL4 IL13 IL10 CD8A CD4
19 acquired immunodeficiency syndrome 29.6 TNF IL2 IL10 IFNG CD4
20 exanthem 29.6 TNF IL2 IL10 IFNG H2AC18 CD8A
21 leishmaniasis 29.6 TNF TLR9 MPI LMLN IL5 IL4
22 chickenpox 29.3 TNF IL4 IL2 IL10 IFNG CD8A
23 trypanosomiasis 29.3 TNF TLR9 IL4 IL10 IFNG H2AC18
24 diarrhea 29.3 TNF IL5 IL2 IL13 IL10 IFNG
25 human immunodeficiency virus type 1 29.3 TNF TLR3 IL2 IL10 IFNG CD4
26 proteasome-associated autoinflammatory syndrome 1 29.3 TNF IL5 IL4 IL13 IL10 IFNG
27 hypereosinophilic syndrome 29.3 IL5 IL4 IL2 IL13 IFNG
28 cutaneous leishmaniasis 29.3 TNF TLR9 MPI LMLN IL5 IL4
29 herpes zoster 29.2 TNF TLR3 IL2 IL10 IFNG CD8A
30 thrombocytopenia 29.1 TNF TLR9 IL4 IL2 IL10 IFNG
31 toxoplasmosis 29.1 TNF TLR9 IL5 IL4 IL10 IFNG
32 visceral leishmaniasis 29.1 TNF TLR9 LMLN IL4 IL2 IL13
33 filariasis 29.1 TNF TLR9 IL5 IL2 IL10 IFNG
34 bacterial infectious disease 28.9 TNF TLR9 TLR3 IL10 IFNG H2AC18
35 peripheral nervous system disease 28.9 TNF IL4 IL2 IL10 IFNG HSPA4
36 viral hepatitis 28.9 TNF TLR9 TLR3 IL4 IL2 IL10
37 allergic disease 28.9 TNF TLR9 IL5 IL4 IL2 IL13
38 parasitic helminthiasis infectious disease 28.9 TNF IL5 IL4 IL2 IL13 IL10
39 disease by infectious agent 28.8 TNF TLR9 IL4 IL2 IL10 IFNG
40 schistosomiasis 28.7 TNF IL5 IL4 IL2 IL13 IL10
41 skin disease 28.5 TNF IL5 IL4 IL2 IL13 IL10
42 autoimmune disease 28.4 TNF TLR9 IL5 IL4 IL2 IL13
43 immune deficiency disease 28.4 TNF TLR9 IL4 IL2 IL13 IL10
44 fungal infectious disease 28.3 TNF IL5 IL4 IL2 IL13 IL10
45 dermatitis 28.2 TNF TLR9 IL5 IL4 IL2 IL13
46 leprosy 3 28.0 TNF TLR9 NELFCD IL5 IL4 IL2
47 parasitic protozoa infectious disease 27.2 TNF TLR9 MT-CYB LMLN IL5 IL4
48 kala-azar 1 11.2
49 punctate inner choroidopathy 10.4 TNF IL10
50 multifocal choroiditis 10.4 TNF IL10

Graphical network of the top 20 diseases related to Mucocutaneous Leishmaniasis:



Diseases related to Mucocutaneous Leishmaniasis

Symptoms & Phenotypes for Mucocutaneous Leishmaniasis

MGI Mouse Phenotypes related to Mucocutaneous Leishmaniasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 CD4 CD8A HSPA4 IFNG IL10 IL13
2 endocrine/exocrine gland MP:0005379 10.07 CD4 CD8A HSPA4 IFNG IL10 IL13
3 digestive/alimentary MP:0005381 10.06 CD4 IFNG IL10 IL13 IL2 IL4
4 hematopoietic system MP:0005397 10.06 CD4 CD8A IFNG IL10 IL13 IL2
5 immune system MP:0005387 10 CD4 CD8A IFNG IL10 IL13 IL2
6 no phenotypic analysis MP:0003012 9.7 CD4 IFNG IL10 IL13 IL2 IL4
7 reproductive system MP:0005389 9.61 HSPA4 IFNG IL10 IL13 IL2 IL4
8 respiratory system MP:0005388 9.23 IFNG IL10 IL13 IL2 IL4 IL5

Drugs & Therapeutics for Mucocutaneous Leishmaniasis

Drugs for Mucocutaneous Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paromomycin Approved, Investigational Phase 2, Phase 3 1263-89-4, 7542-37-2 165580
2
Miltefosine Approved, Investigational Phase 3 58066-85-6 3600
3
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
4
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
5
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
6
meglumine antimoniate Experimental, Investigational Phase 3 133-51-7
7 Pharmaceutical Solutions Phase 3
8 Antiparasitic Agents Phase 3
9 Anti-Infective Agents Phase 3
10 Anti-Bacterial Agents Phase 3
11 Antiprotozoal Agents Phase 3
12 Antifungal Agents Phase 3
13 Amebicides Phase 3
14 Liposomal amphotericin B Phase 3
15
Coal tar Approved Phase 2 8007-45-2
16
Pentoxifylline Approved, Investigational Phase 2 6493-05-6 4740
17 Protective Agents Phase 2
18 Vasodilator Agents Phase 2
19 Phosphodiesterase Inhibitors Phase 2
20 Radiation-Protective Agents Phase 2
21 Antioxidants Phase 2
22 Platelet Aggregation Inhibitors Phase 2
23 Vaccines Phase 1
24 Antimony Sodium Gluconate
25 Anthelmintics

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Completed NCT03829917 Phase 2, Phase 3 Miltefosine and Paromomycin;miltefosine;paromomycin
2 Phase III Clinical Trial for American Tegumentary Leishmaniasis: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Completed NCT01301924 Phase 2, Phase 3 Meglumine antimoniate
3 Phase III Clinical Trial for Mucosal or Mucocutaneous Leishmaniasis. Comparison Between the Standard and Alternative Antimonial Schemes Recruiting NCT01301937 Phase 2, Phase 3 Meglumine antimoniate
4 Efficacy and Safety of Thermotherapy in Combination With Miltefosine Compared to Meglumine Antimoniate and Miltefosine Monotherapy for the Treatment of New World Cutaneous Leishmaniasis: A Phase III, Open Label, Multicenter Randomized Trial Recruiting NCT04515186 Phase 3 Meglumine Antimoniate;Miltefosine
5 Treatment of Bolivian Mucosal Leishmaniasis With Miltefosine, Pentavalent Antimony or Liposomal Amphotericin B Not yet recruiting NCT04799236 Phase 3 Group 1: Miltefosine;Group 2: Pentavalent Antimony;Group 3: Liposomal amphotericin B
6 Treatment of Mucocutaneous Leishmaniasis With Miltefosine Completed NCT01050907 Phase 2 Miltefosine
7 Randomized Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis at Federal District, Brazil Completed NCT01377974 Phase 2 Miltefosine;Standard Treatment Meglumine antimoniate
8 The Association of Miltefosine and Pentoxifylline to Treat Mucosal Leishmaniasis: An Open-label, Randomized Clinical Trial in Brazil Recruiting NCT02530697 Phase 2 Meglumine antimoniate;Miltefosine;Pentoxifylline
9 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate Safety, Tolerability, and Immunogenicity of Leish-111f + MPL-SE Vaccine in Combination With Pentavalent Antimony in Treatment of Mucosal Leishmaniasis Completed NCT00111514 Phase 1
10 Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis Completed NCT02429518 Miltefosine
11 Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis Completed NCT02431429 Miltefosine
12 Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis Available NCT00508963 sodium stibogluconate (Pentostam)

Search NIH Clinical Center for Mucocutaneous Leishmaniasis

Cochrane evidence based reviews: leishmaniasis, mucocutaneous

Genetic Tests for Mucocutaneous Leishmaniasis

Anatomical Context for Mucocutaneous Leishmaniasis

MalaCards organs/tissues related to Mucocutaneous Leishmaniasis:

40
T Cells, Monocytes, Tongue, Bone Marrow, Whole Blood, Neutrophil

Publications for Mucocutaneous Leishmaniasis

Articles related to Mucocutaneous Leishmaniasis:

(show top 50) (show all 1088)
# Title Authors PMID Year
1
Potential distribution of four vectors of American Cutaneous Leishmaniasis: the effect of El Niño and La Niña episodes from the perspective of the ecological niche. 61
33753032 2021
2
Case Report: COVID-19 Misdiagnosed as a Drug Reaction to Miltefosine. 61
33705346 2021
3
Cutaneous and Mucocutaneous Leishmaniasis. 61
33652011 2021
4
Characterization of a protein with unknown function (LinJ.30.3360) in Leishmania amazonensis and Leishmania infantum. 61
33307096 2021
5
Capsid Structure of Leishmania RNA Virus 1. 61
33208443 2021
6
Risk factors for antimony treatment failure in American Cutaneous Leishmaniasis in Northwestern-Argentina. 61
33497376 2021
7
Challenges in diagnosis of genital ulcers: a genital leishmaniasis case series. 61
33759929 2021
8
Leishmaniasis and Trace Element Alterations: a Systematic Review. 61
33405078 2021
9
A retrospective cohort study of the effectiveness and adverse events of intralesional pentavalent antimonials in the treatment of cutaneous leishmaniasis. 61
33285343 2020
10
American cutaneous leishmaniasis associated with degradation of native forest, regardless of economic, social and infrastructure vulnerability. 61
33340442 2020
11
Successful treatment with photodynamic therapy in a patient with nasal mucocutaneous leishmaniasis undergoing treatment with TNFα inhibitor. 61
33331279 2020
12
Mucocutaneous leishmaniasis (espundia). 61
32114490 2020
13
Tongue Nodule as Primary Manifestation of American Cutaneous Leishmaniasis in an Immunocompetent Patient. 61
33372239 2020
14
Case Report: A Single-Center Case Series on Skin Manifestations of Leishmaniasis from a Non-Endemic State in Southern India. 61
33377447 2020
15
Visceral Dissemination of Mucocutaneous Leishmaniasis in a Kidney Transplant Recipient. 61
33396614 2020
16
Duplex qPCR for Leishmania species identification using lesion imprint on filter paper. 61
33053400 2020
17
Novel findings on the role of ficolins and colectins in the innate response against Leishmania braziliensis. 61
32827454 2020
18
Mechanistic and biological characterisation of novel N5-substituted paullones targeting the biosynthesis of trypanothione in Leishmania. 61
32588679 2020
19
Ultrastructure of the Antennae and Sensilla of Nyssomyia intermedia (Diptera: Psychodidae), Vector of American Cutaneous Leishmaniasis. 61
32761144 2020
20
Epidemiology of cutaneous and mucocutaneous leishmaniasis in Nicaragua. 61
33313430 2020
21
Recent advances and new strategies in Leishmaniasis diagnosis. 61
32845368 2020
22
Leishmania Viannia guyanensis, LRV1 virus and extracellular vesicles: a dangerous trio influencing the faith of immune response during muco-cutaneous leishmaniasis. 61
32877837 2020
23
Ecology of Sand Flies (Psychodidae: Phlebotominae) and Natural Infection of Pintomyia townsendi With Leishmania amazonensis in a Cutaneous Leishmaniasis Focus in Colombia. 61
32222761 2020
24
Clinical and epidemiological aspects of American cutaneous leishmaniasis with genital involvement. 61
32768199 2020
25
Influence of Moonlight on Male Mating Aggregations of Nyssomyia whitmani, a Vector of American Cutaneous Leishmaniasis in Brazil. 61
32270870 2020
26
Leishmaniases of the New World from a historical and global perspective, from the 1930s to the 1960s. 61
32997059 2020
27
Astronium fraxinifolium Schott Exerts Leishmanicidal Activity by Providing a Classically Polarized Profile in Infected Macrophages. 61
32347532 2020
28
Interventions for American cutaneous and mucocutaneous leishmaniasis. 61
32853410 2020
29
American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate. 61
32078162 2020
30
Refractory mucocutaneous leishmaniasis resolved with combination treatment based on intravenous pentamidine, oral azole, aerosolized liposomal amphotericin B, and intralesional meglumine antimoniate. 61
32505874 2020
31
Vertical stratification of sand fly diversity in relation to natural infections of Leishmania sp. and blood-meal sources in Jamari National Forest, Rondônia State, Brazil. 61
32807221 2020
32
Health, science and development: the emergence of American cutaneous leishmaniasis as a medical and public health challenge in Amazonas state, Brazil. 61
33111787 2020
33
Identification of Leishmania species by high-resolution DNA dissociation in cases of American cutaneous leishmaniasis. 61
32518010 2020
34
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America. 61
32482148 2020
35
Mucosal and mucocutaneous leishmaniasis in Iran from 1968 to 2018: a narrative review of clinical features, treatments, and outcomes. 61
31943166 2020
36
Differentiation of Leishmania (L.) infantum, Leishmania (L.) amazonensis and Leishmania (L.) mexicana Using Sequential qPCR Assays and High-Resolution Melt Analysis. 61
32486117 2020
37
Immunohistochemical and Molecular Diagnosis of Mucocutaneous and Mucosal Leishmaniasis. 61
31566041 2020
38
Assessment and treatment of cutaneous leishmaniasis in the emergency department. 61
32017482 2020
39
Land use in relation to composition and abundance of phlebotomines (Diptera: Psychodidae) in five foci of domiciliary transmission of cutaneous leishmaniasis in the Andean region of Colombia. 61
31866337 2020
40
Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: A Retrospective Study. 61
31820708 2020
41
Structure-guided approach to identify a novel class of anti-leishmaniasis diaryl sulfide compounds targeting the trypanothione metabolism. 61
31037461 2020
42
Prevalidation of an ELISA for Detection of a New Clinical Entity: Leishmania donovani-Induced Cutaneous Leishmaniasis. 61
32733568 2020
43
Clinical and epidemiological profiles of patients with American cutaneous leishmaniasis from the states of Pernambuco and Amazonas, Brazil. 61
33263681 2020
44
Mucocutaneous leishmaniasis: case report and literature review of a rare endonasal infection. 61
33117486 2020
45
Mucocutaneous leishmaniasis in a cocaine user: diagnostic and therapeutic knowledge. 61
32578710 2020
46
Further insights into the eco-epidemiology of American cutaneous leishmaniasis in the Belem metropolitan region, Pará State, Brazil. 61
33331607 2020
47
Mucocutaneous Leishmaniasis with Rare Manifestation in the Nasal Mucosa and Cartilage Bone Septal. 61
33029438 2020
48
Phlebotomines (Diptera: Psychodidae) from a Urban Park of Belém, Pará State, Northern Brazil and Potential Implications in the Transmission of American Cutaneous Leishmaniasis. 61
31550368 2020
49
Spatial dynamics and socioeconomic factors correlated with American cutaneous leishmaniasis in Pernambuco, Brazil from 2008 to 2017. 61
32348432 2020
50
Cutaneous and mucocutaneous leishmaniasis: experience of a Mediterranean hospital. 61
31931865 2020

Variations for Mucocutaneous Leishmaniasis

Expression for Mucocutaneous Leishmaniasis

Search GEO for disease gene expression data for Mucocutaneous Leishmaniasis.

Pathways for Mucocutaneous Leishmaniasis

Pathways related to Mucocutaneous Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 TNF TLR9 TLR3 IL5 IL4 IL2
2
Show member pathways
13.55 TNF IL5 IL4 IL2 IL13 IL10
3
Show member pathways
13.45 TNF TLR9 TLR3 IL5 IL4 IL2
4
Show member pathways
13.38 TNF IL5 IL4 IL2 IL13 IL10
5
Show member pathways
13.32 TNF IL5 IL4 IL2 IL13 IL10
6
Show member pathways
13.22 TNF TLR9 TLR3 IL2 IL10 IFNG
7
Show member pathways
12.87 TNF IL5 IL4 IL2 IL13 IL10
8 12.84 IL5 IL4 IL2 IL13 IFNG
9
Show member pathways
12.83 TNF TLR9 TLR3 IL2 IFNG
10
Show member pathways
12.69 TNF IL4 IL2 IL10 IFNG CD4
11
Show member pathways
12.65 TNF IL5 IL4 IL2 IL13 IL10
12
Show member pathways
12.65 TNF TLR9 IL5 IL4 IL2 IL10
13
Show member pathways
12.61 TNF IL2 IL10 IFNG CD4
14 12.59 TNF TLR9 TLR3 IL4 IL2 IL10
15
Show member pathways
12.49 IL5 IL4 IL2 IL13 IL10 IFNG
16
Show member pathways
12.39 TNF IL5 IL4 IL13 IFNG
17
Show member pathways
12.35 TNF IL4 IL2 IFNG
18
Show member pathways
12.3 TNF IL5 IL4 IL2 IL13 IL10
19
Show member pathways
12.28 TNF IL4 IL10 IFNG
20 12.26 TNF TLR9 IL10 IFNG
21
Show member pathways
12.23 TNF TLR9 IL2 IL10
22
Show member pathways
12.22 TNF TLR3 IFNG H2AC18
23 12.21 TNF TLR9 TLR3 IFNG
24
Show member pathways
12.2 TNF TLR9 IL4 IFNG
25 12.16 TNF IL2 IL10 CD8A CD4
26
Show member pathways
12.11 TLR9 TLR3 IL5 IL2 IL13
27
Show member pathways
12.06 IL4 IL2 IFNG CD8A CD4
28 12.05 TNF IL4 IL2 IFNG
29 12.03 TNF IL4 IL13 IL10
30 11.98 TNF IL5 IL4 CD8A CD4
31
Show member pathways
11.93 TLR9 TLR3 IL4 IFNG CD4
32 11.92 TNF IL5 IL4 IL2 IL10 IFNG
33 11.87 IL5 IL4 IL2 IL13 IFNG
34
Show member pathways
11.83 TNF TLR9 TLR3 IL2 IL10 IFNG
35
Show member pathways
11.82 TNF IL5 IL4 IL2 IFNG
36 11.78 TNF TLR9 IL2 IL10 IFNG CD8A
37 11.75 TNF IL5 IL4 IL13
38 11.74 TNF TLR9 IL5 IL4 IL10
39
Show member pathways
11.73 TNF IL2 IFNG CD8A
40
Show member pathways
11.69 TNF IL2 IFNG
41 11.69 IL5 IL4 IL10
42 11.64 TNF TLR9 IL10 IFNG
43 11.62 TNF IL4 IL13 IL10
44 11.58 TNF IL2 IFNG
45
Show member pathways
11.58 TNF IFNG HSPA4
46 11.55 TNF IL2 IFNG
47 11.47 TNF TLR9 IL10 IFNG
48
Show member pathways
11.46 TNF IL2 IL10 IFNG
49 11.41 IL5 IL4 IL2 IFNG
50 11.4 TNF IL5 IL4 IL13 IFNG

GO Terms for Mucocutaneous Leishmaniasis

Cellular components related to Mucocutaneous Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 TNF TLR3 IL5 IL4 IL2 IL13
2 extracellular region GO:0005576 9.28 TNF TLR9 IL5 IL4 IL2 IL13

Biological processes related to Mucocutaneous Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.05 TNF TLR9 TLR3 IL5 IL13
2 defense response to bacterium GO:0042742 10.01 TNF TLR9 TLR3 IL10
3 positive regulation of gene expression GO:0010628 10 TNF TLR9 TLR3 IL4 IL13 IFNG
4 positive regulation of protein phosphorylation GO:0001934 9.97 TNF IL2 IFNG CD4
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.96 TNF TLR9 TLR3 CD4
6 positive regulation of tumor necrosis factor production GO:0032760 9.89 TLR9 TLR3 IFNG
7 positive regulation of JNK cascade GO:0046330 9.88 TNF TLR9 TLR3
8 negative regulation of inflammatory response GO:0050728 9.87 IL4 IL2 IL13 IL10
9 cytokine-mediated signaling pathway GO:0019221 9.87 TNF IL5 IL4 IL2 IL13 IL10
10 negative regulation of interleukin-6 production GO:0032715 9.86 TNF TLR9 IL10
11 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.85 TNF TLR9 TLR3
12 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.85 TNF TLR9 TLR3
13 positive regulation of T cell proliferation GO:0042102 9.85 IL4 IL2 CD4
14 positive regulation of interleukin-8 production GO:0032757 9.84 TNF TLR9 TLR3
15 T cell activation GO:0042110 9.81 IL4 CD8A CD4
16 positive regulation of interleukin-6 production GO:0032755 9.81 TNF TLR9 TLR3 IFNG
17 extrinsic apoptotic signaling pathway GO:0097191 9.8 TNF TLR3 IFNG
18 positive regulation of interferon-gamma production GO:0032729 9.8 TNF TLR9 TLR3 IL2
19 positive regulation of inflammatory response GO:0050729 9.8 TNF TLR9 TLR3 IL2 IFNG
20 positive regulation of interleukin-12 production GO:0032735 9.79 TLR9 TLR3 IFNG
21 positive regulation of interleukin-10 production GO:0032733 9.79 TLR9 IL4 IL13
22 negative regulation of endothelial cell apoptotic process GO:2000352 9.78 IL4 IL13 IL10
23 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 TNF IL4 IL2 IL13 IFNG
24 positive regulation of cytokine production GO:0001819 9.76 TNF TLR3 IL10 IFNG
25 positive regulation of JAK-STAT cascade GO:0046427 9.73 TNF IL5 IL10
26 positive regulation of chemokine production GO:0032722 9.73 TNF TLR9 TLR3 IFNG
27 positive regulation of signaling receptor activity GO:2000273 9.72 IL10 IFNG
28 macrophage activation GO:0042116 9.71 IL4 IL13
29 I-kappaB phosphorylation GO:0007252 9.71 TLR9 TLR3
30 negative regulation of amyloid-beta clearance GO:1900222 9.7 TNF IFNG
31 positive regulation of podosome assembly GO:0071803 9.7 TNF IL5
32 response to molecule of bacterial origin GO:0002237 9.7 TLR9 IL10
33 negative regulation of T-helper 17 cell differentiation GO:2000320 9.7 IL4 IL2
34 positive regulation of isotype switching to IgG isotypes GO:0048304 9.69 IL4 IL2
35 positive regulation of mast cell degranulation GO:0043306 9.69 IL4 IL13
36 necroptotic signaling pathway GO:0097527 9.68 TNF TLR3
37 endothelial cell apoptotic process GO:0072577 9.68 TNF IL10
38 positive regulation of mononuclear cell migration GO:0071677 9.66 TNF IL4
39 negative regulation of cytokine production involved in immune response GO:0002719 9.66 TNF IL10
40 positive regulation of cellular respiration GO:1901857 9.65 IL4 IFNG
41 positive regulation of MHC class II biosynthetic process GO:0045348 9.65 IL4 IL10 IFNG
42 positive regulation of B cell proliferation GO:0030890 9.65 TLR9 IL5 IL4 IL2 IL13
43 neuroinflammatory response GO:0150076 9.64 IL4 IFNG
44 type 2 immune response GO:0042092 9.64 IL4 IL10
45 positive regulation of toll-like receptor signaling pathway GO:0034123 9.62 TLR9 TLR3
46 negative regulation of complement-dependent cytotoxicity GO:1903660 9.6 IL4 IL13
47 positive regulation of plasma cell differentiation GO:1900100 9.59 IL2 IL10
48 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 TNF IFNG
49 regulation of isotype switching GO:0045191 9.58 IL4 IL10
50 positive regulation of vitamin D biosynthetic process GO:0060557 9.55 TNF IFNG

Molecular functions related to Mucocutaneous Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL5 IL4 IL2 IL10
2 cytokine activity GO:0005125 9.17 TNF IL5 IL4 IL2 IL13 IL10

Sources for Mucocutaneous Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....